The Oncology Institute, Inc.
TOI
$0.716
$0.09114.56%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.78% | 22.88% | 24.25% | 20.11% | 26.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.78% | 22.88% | 24.25% | 20.11% | 26.25% |
| Cost of Revenue | 29.49% | 31.40% | 33.18% | 27.98% | 27.09% |
| Gross Profit | -10.09% | -13.83% | -15.11% | -8.00% | 22.91% |
| SG&A Expenses | -5.39% | -2.79% | -1.31% | -6.83% | -11.43% |
| Depreciation & Amortization | -7.36% | 14.22% | 17.34% | 32.30% | 49.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.59% | 20.86% | 22.18% | 15.96% | 12.97% |
| Operating Income | 0.22% | -9.95% | -12.33% | 2.74% | 30.34% |
| Income Before Tax | 6.78% | 7.85% | 33.60% | -67.65% | -540.62% |
| Income Tax Expenses | -- | -- | -- | 14.44% | 662.50% |
| Earnings from Continuing Operations | 7.50% | 8.39% | 33.70% | -70.38% | -551.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.50% | 8.39% | 33.70% | -70.38% | -551.42% |
| EBIT | 0.22% | -9.95% | -12.33% | 2.74% | 30.34% |
| EBITDA | -0.77% | -9.53% | -11.89% | 5.59% | 35.17% |
| EPS Basic | 9.84% | 9.06% | 34.27% | -73.27% | -545.18% |
| Normalized Basic EPS | 6.15% | 7.19% | -41.26% | -140.47% | -172.64% |
| EPS Diluted | 7.31% | 10.53% | 34.03% | -5.22% | -12.19% |
| Normalized Diluted EPS | 6.15% | 7.19% | -41.26% | -140.47% | -200.42% |
| Average Basic Shares Outstanding | 2.80% | 0.85% | 1.07% | 0.99% | 1.78% |
| Average Diluted Shares Outstanding | 2.80% | 0.85% | 1.07% | 0.99% | -7.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
